BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2023.
"The fourth quarter marked the successful completion of our corporate transformation. We now have a strong, scalable foundation for growth and innovation," said Masoud Toloue, President and Chief Executive Officer of Quanterix. "Our research business is in a solid position, and we see continued high demand among our research customers. Additionally, we are making progress on our diagnostics efforts, with a dedicated commercial team now in place for our LucentAD p-Tau 217 LDT. We believe we are well positioned to meet the demand for blood-based biomarker testing to support the rollout of new Alzheimer's therapies and to aid providers in the diagnosis of the disease."
Fourth Quarter Financial Highlights
- Revenue was $31.5 million, a 22% increase from $25.8 million for the corresponding prior year period.
- GAAP gross margin was 53.2% as compared to 48.8% for the corresponding prior year period. Non-GAAP gross margin was 46.5% as compared to 41.3% for the corresponding prior year period.
- Net loss was $12.4 million as compared to $18.6 million for the corresponding prior year period.
- Net cash usage in the quarter was $6.4 million as compared to $5.0 million for the corresponding prior year period.
Full Year Financial Highlights
- Revenue was $122.4 million, a 16% increase from $105.5 million for the prior year.
- GAAP gross margin was 57.7% as compared to 44.4% for the prior year. Non-GAAP gross margin was 51.1% as compared to 37.5% for the corresponding prior year.
- Net loss was $32.3 million as compared to $96.7 million for the prior year.
- Net cash usage for the year was $17.4 million as compared to $57.7 million for the corresponding prior year period. Cash, cash equivalents, marketable securities, and restricted cash were $323.9 million as of December 31, 2023, as compared to $341.3 million as of December 31, 2022.
Operational and Business Highlights
- Quanterix's six quarter corporate transformation program is now complete. Newly developed assays are now in production and available to customers.
- Quanterix announced first collaborations with five health networks to aid the diagnosis and clinical management of individuals with Alzheimer's Disease. AdventHealth, Mass General Brigham, Mayo Clinic, MUSC, and UPMC will leverage Quanterix technology and assays to streamline care for Alzheimer's patients.
- Eli Lilly announced the launch of their p-Tau 217 blood-based diagnostics test, which runs on the Quanterix platform.
- Continued progress on two important studies for multi-marker test development and validation. Phase 1 is now complete for both the CANTATE and BioHermes trials, with readouts expected in 2024. Quanterix also advanced several US-based prospective clinical studies supporting leading academic research centers, the University of Pennsylvania Health System and UPMC, to evaluate Simoa® blood-based biomarkers as part of Alzheimer's Disease clinical care workflows.
2024 Full Year Business Outlook
Management expects full-year 2024 revenue to be in the range of $139 to $144 million. This guide is for our research-only business and does not include revenues from Diagnostics testing, which to date have not been material. GAAP gross margin percentage is expected to be in the range of 57-61%, and non-GAAP gross margin percentage is expected to be in the range of 51-55%. Additionally, the Company anticipates 2024 cash usage in the range of $25 to $30 million.
For additional information on the non-GAAP financial measures included in this press release, please see "Use of Non-GAAP Financial Measures" and "Reconciliation of GAAP to Non-GAAP Financial Measures" below.
Conference Call
In conjunction with this announcement, the Company will host a conference call on February 29, 2024 at 4:30 p.m. E.T. Click here to pre-register for the conference call and obtain your dial-in number and passcode.
Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at http://www.quanterix.com. An archived webcast replay will be available on the Company's website for one year.
Financial Highlights
| Quanterix Corporation | |||||||||||||||
| Consolidated Statements of Operations | |||||||||||||||
| (Unaudited and in thousands, except per share data) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
| Revenues: | |||||||||||||||
| Product revenue | $ | 20,821 | $ | 16,674 | $ | 79,460 | $ | 69,808 | |||||||
| Service and other revenue | 10,230 | 8,767 | 40,299 | 34,495 | |||||||||||
| Collaboration and license revenue | 146 | 170 | 1,380 | 649 | |||||||||||
| Grant revenue | 352 | 213 | 1,229 | 570 | |||||||||||
| Total revenues | 31,549 | 25,824 | 122,368 | 105,522 | |||||||||||
| Costs of goods sold and services: | |||||||||||||||
| Cost of product revenue | 10,025 | 9,631 | 32,636 | 40,809 | |||||||||||
| Cost of service and other revenue | 4,725 | 3,601 | 19,086 | 17,907 | |||||||||||
| Total costs of goods sold and services | 14,750 | 13,232 | 51,722 | 58,716 | |||||||||||
| Gross profit | 16,799 | 12,592 | 70,646 | 46,806 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 6,991 | 5,600 | 24,857 | 25,890 | |||||||||||
| Selling, general, and administrative | 24,172 | 19,272 | 90,241 | 91,995 | |||||||||||
| Other lease costs | 1,016 | 669 | 3,712 | 1,278 | |||||||||||
| Impairment and restructuring | 1,570 | 9,006 | 1,537 | 29,347 | |||||||||||
| Total operating expenses | 33,749 | 34,547 | 120,347 | 148,510 | |||||||||||
| Loss from operations | (16,950 | ) | (21,955 | ) | (49,701 | ) | (101,704 | ) | |||||||
| Interest income (expense), net | 4,319 | 2,815 | 15,839 | 5,131 | |||||||||||
| Other income (expense), net | 363 | 614 | 2,247 | (62 | ) | ||||||||||
| Loss before income taxes | (12,268 | ) | (18,526 | ) | (31,615 | ) | (96,635 | ) | |||||||
| Income tax (expense) benefit | (141 | ) | (75 | ) | (719 | ) | (65 | ) | |||||||
| Net loss | $ | (12,409 | ) | $ | (18,601 | ) | $ | (32,334 | ) | $ | (96,700 | ) | |||
| Net loss per common share, basic and diluted | $ | (0.33 | ) | $ | (0.50 | ) | $ | (0.86 | ) | $ | (2.61 | ) | |||
| Weighted-average common shares outstanding, basic and diluted | 37,890 | 37,160 | 37,594 | 36,991 | |||||||||||
| Quanterix Corporation | |||||
| Consolidated Balance Sheets | |||||
| (Unaudited and in thousands) | |||||
| December 31, 2023 | December 31, 2022 | ||||
| ASSETS | |||||
| Current assets: | |||||
| Cash and cash equivalents | $ | 174,422 | $ | 338,740 | |
| Marketable securities | 146,902 | - | |||
| Accounts receivable | 25,414 | 19,017 | |||
| Inventory | 22,365 | 16,786 | |||
| Prepaid expenses and other current assets | 9,291 | 6,860 | |||
| Total current assets | 378,394 | 381,403 | |||
| Restricted cash | 2,604 | 2,597 | |||
| Property and equipment, net | 17,926 | 20,162 | |||
| Intangible assets, net | 6,034 | 7,516 | |||
| Operating lease right-of-use assets | 18,251 | 21,223 | |||
| Other non-current assets | 1,802 | 1,298 | |||
| Total assets | $ | 425,011 | $ | 434,199 | |
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||
| Current liabilities: | |||||
| Accounts payable | $ | 5,048 | $ | 3,836 | |
| Accrued compensation and benefits | 13,659 | 10,658 | |||
| Accrued expenses and other current liabilities | 6,041 | 5,133 | |||
| Deferred revenue | 9,468 | 8,644 | |||
| Operating lease liabilities | 4,241 | 2,687 | |||
| Total current liabilities | 38,457 | 30,958 | |||
| Deferred revenue, net of current portion | 1,227 | 1,415 | |||
| Operating lease liabilities, net of current portion | 37,223 | 41,417 | |||
| Other non-current liabilities | 1,177 | 1,469 | |||
| Total liabilities | 78,084 | 75,259 | |||
| Total stockholders' equity | 346,927 | 358,940 | |||
| Total liabilities and stockholders' equity | $ | 425,011 | $ | 434,199 | |
| Quanterix Corporation | ||||||||
| Consolidated Statements of Cash Flows | ||||||||
| (Unaudited and in thousands) | ||||||||
| Year Ended December 31, | ||||||||
2023 | 2022 | |||||||
| Cash flows from operating activities: | ||||||||
| Net loss | $ | (32,334 | ) | $ | (96,700 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization expense | 6,364 | 5,349 | ||||||
| Credit losses (gains) on accounts receivable | 336 | (301 | ) | |||||
| Accretion of marketable securities | (1,964 | ) | - | |||||
| Operating lease right-of-use asset amortization | 2,015 | 715 | ||||||
| Stock-based compensation expense | 16,764 | 15,442 | ||||||
| Impairment | 1,570 | 25,592 | ||||||
| Other operating activity | 150 | (439 | ) | |||||
| Changes in assets and liabilities: | ||||||||
| Accounts receivable | (6,695 | ) | 5,156 | |||||
| Inventory | (5,364 | ) | 5,386 | |||||
| Prepaid expenses and other current assets | (2,371 | ) | (568 | ) | ||||
| Other non-current assets | (775 | ) | (909 | ) | ||||
| Accounts payable | 1,189 | (5,362 | ) | |||||
| Accrued compensation and benefits, accrued expenses, and other current liabilities | 4,276 | (3,976 | ) | |||||
| Deferred revenue | 635 | 2,599 | ||||||
| Operating lease liabilities | (2,645 | ) | (266 | ) | ||||
| Other non-current liabilities | (53 | ) | 10 | |||||
| Net cash used in operating activities | (18,902 | ) | (48,272 | ) | ||||
| Cash flows from investing activities: | ||||||||
| Purchases of marketable debt securities | (175,613 | ) | - | |||||
| Proceeds from marketable debt securities | 31,000 | - | ||||||
| Purchases of property and equipment | (3,788 | ) | (11,726 | ) | ||||
| Proceeds from RADx grant on assets purchased | - | 520 | ||||||
| Net cash used in investing activities | (148,401 | ) | (11,206 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Proceeds from common stock issued under stock plans | 2,889 | 2,311 | ||||||
| Payments for employee taxes withheld on stock-based compensation awards | (198 | ) | - | |||||
| Sale of common stock in underwritten public offering, net | - | - | ||||||
| Payments on notes payable | - | - | ||||||
| Net cash provided by financing activities | 2,691 | 2,311 | ||||||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | (164,612 | ) | (57,167 | ) | ||||
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 301 | (538 | ) | |||||
| Cash, cash equivalents, and restricted cash at beginning of period | 341,337 | 399,042 | ||||||
| Cash, cash equivalents, and restricted cash at end of period | $ | 177,026 | $ | 341,337 | ||||
Use of Non-GAAP Financial Measures
To supplement our financial statements presented on a U.S. GAAP basis, we present non-GAAP gross profit, non-GAAP gross margin, non-GAAP total operating expenses, and non-GAAP loss from operations, which are calculated by including shipping and handling costs for product sales within cost of goods sold instead of within selling, general, and administrative expenses. Management uses these non-GAAP measures to evaluate our operating performance in a manner that allows for meaningful period-to-period comparison and analysis of trends in our business and our competitors. Management believes that presentation of these non-GAAP measures provides useful information to investors in assessing our operating performance within our industry and in order to allow comparability to the presentation of other companies in our industry where shipping and handling costs are included in cost of goods sold for products. The non-GAAP financial information presented here should be considered in conjunction with, and not as a substitute for, the financial information presented in accordance with U.S. GAAP. Set forth below is a reconciliation of non-GAAP gross profit, non-GAAP gross margin, non-GAAP total operating expenses, and non-GAAP loss from operations to their most directly comparable GAAP financial measures.
Reconciliation of GAAP to Non-GAAP Financial Measures
| Quanterix Corporation | |||||||||||||||
| Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures | |||||||||||||||
| (Unaudited and in thousands, except percentages) | |||||||||||||||
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||
2023 | 2022 | 2023 | 2022 | ||||||||||||
| GAAP gross profit | $ | 16,799 | $ | 12,592 | $ | 70,646 | $ | 46,806 | |||||||
| Shipping and handling costs (1) | (2,141 | ) | (1,923 | ) | (8,146 | ) | (7,211 | ) | |||||||
| Non-GAAP gross profit | $ | 14,658 | $ | 10,669 | $ | 62,500 | $ | 39,595 | |||||||
| GAAP revenue | $ | 31,549 | $ | 25,824 | $ | 122,368 | $ | 105,522 | |||||||
| GAAP gross margin (gross profit as % of revenue) | 53.2 | % | 48.8 | % | 57.7 | % | 44.4 | % | |||||||
| Non-GAAP gross margin (non-GAAP gross profit as % of revenue) | 46.5 | % | 41.3 | % | 51.1 | % | 37.5 | % | |||||||
| GAAP total operating expenses | $ | 33,749 | $ | 34,547 | $ | 120,347 | $ | 148,510 | |||||||
| Shipping and handling costs (1) | (2,141 | ) | (1,923 | ) | (8,146 | ) | (7,211 | ) | |||||||
| Non-GAAP total operating expenses | $ | 31,608 | $ | 32,624 | $ | 112,201 | $ | 141,299 | |||||||
| GAAP loss from operations | $ | (16,950 | ) | $ | (21,955 | ) | $ | (49,701 | ) | $ | (101,704 | ) | |||
| Non-GAAP loss from operations | $ | (16,950 | ) | $ | (21,955 | ) | $ | (49,701 | ) | $ | (101,704 | ) | |||
| (1) Shipping and handling costs, which include freight and other activities costs associated with product shipments, are captured within operating expenses in our consolidated statements of operations. During the three months ended December 31, 2023 and 2022, we incurred $2.1 million and $1.9 million, respectively, of shipping and handling costs recorded within operating expenses. During the year ended December 31, 2023 and 2022, we incurred $8.1 million and $7.2 million, respectively, of shipping and handling costs within operating expenses. | |||||||||||||||
About Quanterix
From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is driving breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification of conventional analog methods. Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,700 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.
Forward-Looking Statements
Quanterix's current financial results, as discussed in this press release, are preliminary and unaudited, and subject to adjustment. This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements about Quanterix's financial performance, including statements under the header "Full Year Business Outlook" set forth above, and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements in this press release are based on Quanterix's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix's actual results to differ from those expressed or implied in the forward-looking statements in this press release include, but are not limited to, those described in our periodic reports filed with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contacts
Media:
PAN Communications
Maya Nimnicht
510-334-6273
quanterix@pancomm.com
Investor Relations:
ir@quanterix.com
